View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 28, 2018

Abbott gets CE-Mark for blood test to predict heart attack risk

Abbott has obtained the European CE-Mark for its Architect Stat High Sensitive Troponin-I blood test designed to predict the chances of a heart attack or other cardiac events in seemingly healthy people.

Abbott has obtained the European CE-Mark for its Architect Stat High Sensitive Troponin-I blood test designed to predict the chances of a heart attack or other cardiac events in seemingly healthy people.

The test uses a cardiac-specific biomarker to identify at-risk adults potentially months to years in advance.

“Research showed that measuring a person’s troponin levels with Abbott’s new blood test can offer better predictive information when used in conjunction with the existing standard of care.”

Current European guidelines recommend analysis of indirect heart health factors such as cholesterol levels, blood pressure, diabetes or smoking status to establish the risk of a patient developing future heart disease.

Research showed that measuring a person’s troponin levels with Abbott’s new blood test can offer better predictive information when used in conjunction with the existing standard of care.

Abbott diagnostics business global medical and scientific affairs senior medical director Agim Beshiri said: “We finally have a heart-specific tool when trying to determine a patient’s chances of developing heart disease.

“This advancement has the potential to transform how doctors and patients prevent heart disease. Because the high sensitive troponin-I test can be part of any routine health check, it fits easily into existing healthcare practices.”

The High Sensitive Troponin-I blood test has been studied over the past five years in emergency rooms across Europe for fast and accurate detection of heart attacks.

As the test can identify very low troponin levels, it is expected to be useful in people without any reported symptoms. It can be used during a routine health exam at the time of standard blood draw.

The information provided by the test can help doctors in delivering correct treatment for people at high risk. It can also avoid unnecessary tests, medication and costs for lower-risk patients.

Related Companies

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU